Boston Scientific Corporation (NYSE:BSX) is one of the best stocks to invest in according to Two Sigma Advisors with huge ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Investors were hoping for a positive update from Boston Scientific at the Bernstein Annual Strategic Decisions Conference today, but management merely reiterated its previous guidance for the year.

Watchman isn’t hitting the mark for Boston Scientific. Weak demand for the Left Atrial Appendage (LAA) Closure Device, which was once a jewel in the Marlborough, MA-based company’s crown, sent shares ...

May 27 (Reuters) - Boston Scientific (BSX.N), opens new tab shares sank to their lowest in over two years on Wednesday, after the medical device maker warned it was facing pressure due to softer ...

McLaren Port Huron has introduced the Watchman device, making it the first hospital in St. Clair County to offer this treatment for non-valvular atrial fibrillation, according to a community ...

Data highlights the WATCHMAN FLX device provided statistically superior protection from bleeding, demonstrated similar efficacy compared to blood thinners in patients with non-valvular atrial ...

Add Yahoo as a preferred source to see more of our stories on Google. Boston Scientific’s Watchman FLX Pro device, the latest version of its left atrial appendage closure system, was approved by the ...

When it comes to people with non-valvular atrial fibrillation (AFib), the risk of stroke is five times greater than that of those without it. While your heart valves function correctly, “electrical ...

Data highlights the WATCHMAN FLX device provided statistically superior protection from bleeding, demonstrated similar efficacy compared to blood thinners in patients with non-valvular atrial ...

The study evaluated the WATCHMAN FLX™ Left Atrial Appendage Closure (LAAC) Device compared to non-vitamin K antagonist oral anticoagulants (NOACs) as a first-line option for stroke risk reduction in a ...

MARLBOROUGH, Mass. and NEW ORLEANS, March 28, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced that the CHAMPION-AF global clinical trial met all primary and secondary ...